NEUIMMUNE
NeuImmune is a biopharmaceutical company that develops innovative vaccines and biopharmaceuticals through the precision glycoengineering and delivery of biologics that address important medical and public health needs. The company provides safe and effective prophylactic and therapeutic treatments based on their novel biomanufacturing and delivery platforms in order to meet these needs.
NEUIMMUNE
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2020-01-01
Address:
Sykesville, Maryland, United States
Country:
United States
Website Url:
http://www.neuimmune.com
Status:
Active
Email Addresses:
[email protected]
Total Funding:
105 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Content Delivery Network Mobile Non Scaleable Content Nginx IPv6 ReCAPTCHA Apple Mobile Web App Capable DigiCert SSL
Similar Organizations
Aspen Neuroscience
Aspen Neuroscience is a biotechnology company that specializes in personalized cell therapies.
Genocea Biosciences
Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Current Employees Featured
Founder
Official Site Inspections
http://www.neuimmune.com
- Host name: 134.152.208.35.bc.googleusercontent.com
- IP address: 35.208.152.134
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "NeuImmune"
Home - NeuImmune
Our vision, through the engineering of precision biologics, is to position NeuImmune as the leading glycoprotein therapeutics company focused on addressing enzyme replacement …See details»
Our Leadership - NeuImmune
Dr. Fuerst has led the research, development, and manufacturing of biological products for 30+ years. Scientific Founder and Research Director at MedImmune; Executive Director R&D, Sanofi; EVP CSO, PharmAthene. Director of …See details»
Our Partners - NeuImmune
Collaborations have been a critical part of NeuImmune’s growth strategy and will continue to be an emphasis for our future. The company is actively exploring alliances that complement our …See details»
NeuImmune - Crunchbase Company Profile & Funding
NeuImmune is a biopharmaceutical company that develops innovative vaccines and biopharmaceuticals through the precision glycoengineering and delivery of biologics that …See details»
Neuimmune, Inc. Company Profile | Sykesville, MD | Competitors ...
Find company research, competitor information, contact details & financial data for Neuimmune, Inc. of Sykesville, MD. Get the latest business insights from Dun & Bradstreet.See details»
Steve Horrigan - Advisor at NeuImmune - The Org
Horrigan currently serves as the chief scientific officer for Noble Life Sciences, a leading pre-clinical research organization. At Noble, he leads a team to determine pharmacology and …See details»
Kenneth Carter - Key Advisor at NeuImmune - The Org
Dr. Carter is a key advisor to NeuImmune and will serve on its Board of Directors. He is a dynamic biotechnology industry executive and scientific leader with deep experience in early-stage …See details»
NeuImmune Company Profile 2024: Valuation, Funding
Developer of glyco-engineered Chinese hamster ovary cells platform intended for the production of human-like glycoproteins. The company's platform leverages AI-driven design to optimize …See details»
RePORT 〉 RePORTER - National Institutes of Health
Awardee Organization NEUIMMUNE BIOLOGICS, INC. Description. Abstract Text. ABSTRACT Globally, more than 71 million people are infected with Hepatitis C virus (HCV), with 1-2 million …See details»
Resources - NeuImmune
Ginkgo Technology Network Launches, Providing an Integrated R&D Experience with Capabilities from Over 25 Inaugural Partners. Presentation. Publications. ICAM-1 Niemann Pick Disease. …See details»
Alexander K. Andrianov - Co-Founder and Scientific
Dr. Andrianov is a scientific founder of NeuImmune and serves as a Scientific Advisory Board. He is currently a Research Professor at the Institute of Bioscience and Biotechnology Research (IBBR), University of Maryland.See details»
Neurimmune to regain global rights to brain amyloid depleter for …
ZURICH, Switzerland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Neurimmune announced today that it regained global rights to aducanumab, a recombinant human antibody developed to deplete …See details»
Neurimmune AG - Swiss Biotech
Neurimmune is a biopharmaceutical company translating human immune memory into transformative antibody therapeutics. Neurimmune develops drug candidates for CNS and …See details»
Promising Phase 1 results for antibody NI006 in ATTR …
May 20, 2023 · Neurimmune announced today that primary results of its Phase 1 proof-of-concept study of NI006, a recombinant human antibody to deplete amyloid deposits in ATTR …See details»
Our Pipeline - NeuImmune
Learn more about NeuImmune by downloading our most recent corporate presentationSee details»
Pipeline – Neurimmune
In 2024, Neurimmune regained global rights from Biogen to NI101SQ and the entire aducanumab portfolio. *The U.S. FDA granted accelerated approval for intravenously administered …See details»
Neurimmune enters into a collaboration and license agreement …
Jul 1, 2022 · Neurimmune AG today announced that it has entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, to …See details»
geCHO BioDesign Platform - NeuImmune
NeuImmune’s geCHO BioDesign platform has two major components: the geCHO cell line panel and the AI platform for identifying optimal glycoforms and cell line optimization.See details»
ICAM-1 Targeting Technology - NeuImmune
Our approach is to target the CNS and peripheral delivery of the optimal enzyme through the ICAM-1 receptor. ICAM-1 is overexpressed in all tissues during.See details»
Home – Neurimmune
Neurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune’s pipeline comprises drug candidates for Alzheimer’s disease, …See details»